Corvus Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 7 Sell calls were actually followed by a +37% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -9.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 21.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -32.6% | Better than 12% |
| Return on invested capital | -37.1% | Better than 8% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -33.1% | Better than 15% |
| 6-month return | -23.3% | Better than 24% |
| 12-month return (ex latest month) | 24.3% | Better than 64% |
| Distance below 52-week high | 64.1% | Better than 8% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.2x | Better than 89% |
| Debt to assets | 1.3% | Better than 91% |
| Interest coverage | -2,881.7x | Better than 1% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 182.6% | Better than 93% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 10.01
- Open
- 9.84
- Day range
- 9.56 - 10.04
- Avg price
- 9.70
- Volume
- 927.52K
- Turnover
- 9.00M
- Turnover ratei
- 1.27%
- Volume ratioi
- 1.16
- Amplitudei
- 4.85%
- 52-week rangei
- 6.39 - 26.95
Valuation
- P/Ei
- -18.25
- P/E (TTM)i
- -13.43
- P/Bi
- 3.91
- EPSi
- -0.53
- Book value / shi
- 2.47
- Net profit
- -44.71M
- Net assets
- 208.35M
Share structure
- Market cap
- 815.69M
- Float capi
- 706.07M
- Shares out
- 84.35M
- Float sharesi
- 73.02M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-03-23
64.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.09M net over the window
Short interest
- Shares short
- 17.76M
- % of floati
- 21.11%
- Days to coveri
- 18.85
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
Corvus Pharmaceuticals last traded at 9.67. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Corvus Pharmaceuticals's market cap?
About 815.69M.
What is the P/E ratio of Corvus Pharmaceuticals?
The trailing twelve-month P/E is -13.43. The Valuation tab shows it against the stock's own five-year range.
Does Corvus Pharmaceuticals pay a dividend?
Corvus Pharmaceuticals does not currently pay a regular dividend.
Is Corvus Pharmaceuticals a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 27.33, which implies 182.6% upside from the current price. This is not investment advice.
What is Corvus Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Corvus Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Corvus Pharmaceuticals discussion 0 comments